Axonics Inc
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retent… Read more
Axonics Inc (0I3) - Total Assets
Latest total assets as of June 2024: €747.34 Million EUR
Based on the latest financial reports, Axonics Inc (0I3) holds total assets worth €747.34 Million EUR as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Axonics Inc - Total Assets Trend (2016–2023)
This chart illustrates how Axonics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Axonics Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Axonics Inc's total assets of €747.34 Million consist of 68.3% current assets and 31.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 14.6% |
| Accounts Receivable | €57.24 Million | 8.0% |
| Inventory | €79.94 Million | 11.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €81.38 Million | 11.3% |
| Goodwill | €99.42 Million | 13.8% |
Asset Composition Trend (2016–2023)
This chart illustrates how Axonics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Axonics Inc's current assets represent 68.3% of total assets in 2023, a decrease from 80.4% in 2016.
- Cash Position: Cash and equivalents constituted 14.6% of total assets in 2023, down from 75.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 24.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 13.8% of total assets.
Axonics Inc Competitors by Total Assets
Key competitors of Axonics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Axonics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Axonics Inc generates 0.51x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Axonics Inc is currently not profitable relative to its asset base.
Axonics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.96 | 14.19 | 7.58 |
| Quick Ratio | 7.11 | 12.01 | 6.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €454.89 Million | € 423.31 Million | € 102.28 Million |
Axonics Inc - Advanced Valuation Insights
This section examines the relationship between Axonics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.14 |
| Latest Market Cap to Assets Ratio | 4.57 |
| Asset Growth Rate (YoY) | 9.2% |
| Total Assets | €719.92 Million |
| Market Capitalization | $3.29 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Axonics Inc's assets at a significant premium ( 4.57x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Axonics Inc's assets grew by 9.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Axonics Inc (2016–2023)
The table below shows the annual total assets of Axonics Inc from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €719.92 Million | +9.19% |
| 2022-12-31 | €659.35 Million | +20.33% |
| 2021-12-31 | €547.95 Million | +60.12% |
| 2020-12-31 | €342.21 Million | +55.67% |
| 2019-12-31 | €219.82 Million | +27.87% |
| 2018-12-31 | €171.91 Million | +484.48% |
| 2017-12-31 | €29.41 Million | +170.93% |
| 2016-12-31 | €10.86 Million | -- |